BR112022021910A2 - Inibidores da proteína bcl-2 - Google Patents

Inibidores da proteína bcl-2

Info

Publication number
BR112022021910A2
BR112022021910A2 BR112022021910A BR112022021910A BR112022021910A2 BR 112022021910 A2 BR112022021910 A2 BR 112022021910A2 BR 112022021910 A BR112022021910 A BR 112022021910A BR 112022021910 A BR112022021910 A BR 112022021910A BR 112022021910 A2 BR112022021910 A2 BR 112022021910A2
Authority
BR
Brazil
Prior art keywords
bcl
protein inhibitors
formula
various
inhibitors
Prior art date
Application number
BR112022021910A
Other languages
English (en)
Inventor
Robert Pinchman Joseph
Duane Bunker Kevin
Qinhua Huang Peter
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of BR112022021910A2 publication Critical patent/BR112022021910A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INIBIDORES DA PROTEÍNA BCL-2. Vários inibidores da proteína Bcl-2 são descritos, juntamente com métodos de uso dos mesmos para tratar condições caracterizadas por proliferação celular excessiva, como câncer e tumores. Em várias modalidades, os inibidores da proteína Bcl-2 são compostos ou sais farmaceuticamente aceitáveis das seguintes Fórmula (I), em que as variáveis na Fórmula (I) são definidas no presente documento. (I)
BR112022021910A 2020-04-28 2021-04-26 Inibidores da proteína bcl-2 BR112022021910A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063016760P 2020-04-28 2020-04-28
PCT/US2021/029181 WO2021222114A1 (en) 2020-04-28 2021-04-26 Bcl-2 protein inhibitors

Publications (1)

Publication Number Publication Date
BR112022021910A2 true BR112022021910A2 (pt) 2022-12-13

Family

ID=78332399

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021910A BR112022021910A2 (pt) 2020-04-28 2021-04-26 Inibidores da proteína bcl-2

Country Status (12)

Country Link
US (1) US20230167105A1 (pt)
EP (1) EP4107152A4 (pt)
JP (1) JP2023524439A (pt)
KR (1) KR20230002483A (pt)
CN (1) CN115461335A (pt)
AU (1) AU2021263568A1 (pt)
BR (1) BR112022021910A2 (pt)
CA (1) CA3173843A1 (pt)
IL (1) IL297586A (pt)
MX (1) MX2022010512A (pt)
TW (1) TW202206424A (pt)
WO (1) WO2021222114A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114144411A (zh) * 2019-07-10 2022-03-04 里科瑞尔姆Ip控股有限责任公司 Bcl-2蛋白抑制剂
WO2023215449A1 (en) 2022-05-06 2023-11-09 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2023215471A1 (en) 2022-05-06 2023-11-09 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
TW202400589A (zh) 2022-05-06 2024-01-01 美商樹線生物科學公司 四氫異喹啉異雙功能ｂｃｌ—ｘｌ降解劑
WO2024078581A1 (en) * 2022-10-12 2024-04-18 Appicine Therapeutics (Hk) Limited Selective bcl-xl protac compounds and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102447884B1 (ko) * 2016-04-21 2022-09-27 바이오벤처스, 엘엘씨 항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도
CN111801320A (zh) * 2018-01-10 2020-10-20 里科瑞尔姆Ip控股有限责任公司 苯甲酰胺化合物
CA3088253A1 (en) * 2018-01-22 2019-07-25 Bioventures, Llc Bcl-2 proteins degraders for cancer treatment
CN114144411A (zh) * 2019-07-10 2022-03-04 里科瑞尔姆Ip控股有限责任公司 Bcl-2蛋白抑制剂

Also Published As

Publication number Publication date
CN115461335A (zh) 2022-12-09
WO2021222114A1 (en) 2021-11-04
TW202206424A (zh) 2022-02-16
JP2023524439A (ja) 2023-06-12
KR20230002483A (ko) 2023-01-05
IL297586A (en) 2022-12-01
US20230167105A1 (en) 2023-06-01
MX2022010512A (es) 2022-11-16
CA3173843A1 (en) 2021-11-04
EP4107152A1 (en) 2022-12-28
AU2021263568A1 (en) 2022-09-22
EP4107152A4 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
BR112022021910A2 (pt) Inibidores da proteína bcl-2
BR112021012635A2 (pt) Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
BR112021024674A2 (pt) Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112021019722A2 (pt) Compostos de piperidina 3-substituídos para inibição de cbl-b, e uso de inibidor de cbl-b em combinação com vacina contra câncer e/ou vírus oncolítico
BR112017024331A2 (pt) composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto
BRPI0517921A (pt) métodos para preparar compostos de indazol
BR112022017393A2 (pt) Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
BR112018070161A2 (pt) moduladores de receptores de estrogênio
BR112021023825A2 (pt) Inibidores heterobicíclicos de mat2a e métodos de uso para tratamento de câncer
BR112016001457A2 (pt) Inibidores de fatores de transcrição e usos dos mesmos
MX2022000310A (es) Inhibidores de proteina bcl-2.
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
BR112022000713A2 (pt) Imidazopirimidinas como inibidores de eed e o uso das mesmas
BR112021016833A2 (pt) Compostos com atividade indutora de ferroptose e métodos de seu uso
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112022019020A2 (pt) Proteínas de fusão de il12 mascaradas e métodos de uso das mesmas
BR112016028888A2 (pt) compostos que compreendem o sistema 1,1',2,5'-tetra hidro espiro [indol-3,2'-pirrol]-2,5'-diona como inibidores de interação proteína-proteína p53-mdm2
BR112021013362A2 (pt) Agentes rnai para inibição da expressão de hif-2 alfa (epas1), suas composições e métodos de uso
BR112020024412A8 (pt) Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112022012969A2 (pt) Moléculas de ligação, molécula de ácido nucleico isolada, vetor, célula hospedeira, composição farmacêutica, usos da molécula de ligação, métodos para produzir a molécula de ligação, tratar um indivíduo com câncer e suprarregular ou prolongar a atividade de células t citotóxicas em um indivíduo com câncer
BR112022011426A2 (pt) Uso de inibidores de atr em combinação com inibidores de parp

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing